On May 31, the fine chemicals group Axyntis will definitively close its Calais plant, belonging to its subsidiary Synthexim. Placed in receivership at the end of last year, the factory is in liquidation, for lack of a buyer. Of the hundred employees affected, around thirty may be reclassified within the group. But what could be more paradoxical than closing a factory capable of producing pharmaceutical intermediates and active ingredients, while the problems of drug shortages are getting worse and the government is pushing for relocation?
Founding President of Axyntis, David Simonnet remarkably defended himself, on May 10, before a Senate Commission investigating drug shortages, and reproached him for destroying precious capacities.
This article is reserved for our Info Chimie and Usine Nouvelle subscribers
Support expert journalism.
Selected for you
#Édito #Limits #relocation #fine #chemicals #Axyntis